Buparlisib (BKM-120) is a BBB penetrable pan-PI3K inhibitor targeting all four class I PI3K isoforms (p110α, p110β, p110δ and p110γ) and is under clinical development for various brain cancers (Table 1). Here, PIK3CB is linked to brain cancer.